| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | XMD14-99 | GDSC1000 | pan-cancer | AAC | -0.005 | 0.9 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.0051 | 0.9 |
| mRNA | PL-DI | CTRPv2 | pan-cancer | AAC | -0.0042 | 0.9 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | HG-5-88-01 | GDSC1000 | pan-cancer | AAC | -0.0066 | 0.9 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | KX2-391 | CTRPv2 | pan-cancer | AAC | -0.0041 | 0.9 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | 0.0071 | 0.9 |
| mRNA | dabrafenib | CTRPv2 | pan-cancer | AAC | 0.0061 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0041 | 0.9 |